stockrowScholar Rock Holding Corporation
SRRK Healthcare Biotechnology
Scholar Rock Holding Corporation’s revenue for fiscal 2022 (year ended December 2022) was $33.2 million.
- EPS
- +14.3%
- Free cash flow
- +8.88%
- Total debt
- +294.3%
Quarter to June 2026, against a year earlier
Follow SRRK
Alert me
Scholar Rock Holding Corporation (SRRK) EV/FCF
As of 6 November 2026, Scholar Rock Holding Corporation (SRRK) trades at a EV/FCF of −19.6×. Over the past ten years it has ranged from −27.6× (March 2021) to 37.5× (December 2019); the current reading is higher than 9% of that period.
EV/FCF, daily
Embed this chart
Annual newest first
| Period | EV/FCF | Change |
|---|---|---|
| FY2022 | −2.3× | — |
| FY2021 | −5.4× | — |
| FY2020 | −18.3× | — |
| FY2019 | −3.2× | — |
| FY2016 | −0.5× | — |
Quarterly newest first
| Period | EV/FCF | Change |
|---|---|---|
| Mar 2022 | −2.2× | — |
| Dec 2021 | −5.4× | — |
| Sep 2021 | −8.2× | — |
| Jun 2021 | −7.4× | — |
| 9 more quarters | Free account |
Against its own ten years
EV/FCF against peers
| Company | EV/FCF |
|---|---|
| BLTE Belite Bio, Inc. Sponsored ADR compare | −79.2× |
| MANE Veradermics Incorporated compare | −35.5× |
| KOD Kodiak Sciences Inc. compare | −35.4× |
| CGON CG Oncology, Inc. compare | −26.2× |
| PTCT PTC Therapeutics, Inc. compare | −24.0× |
| SRRK Scholar Rock Holding Corporation | −19.0× |
| ERAS Erasca, Inc. compare | −15.5× |
| COGT Cogent Biosciences, Inc. compare | −14.6× |
| IMVT Immunovant, Inc. compare | −12.2× |
What EV/FCF is
EV/Free CF shows how the value of a whole company, debt included, compares with the free cash its business produces.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ (Operating Cash Flow (TTM) + Property, Plant, Equipment Change (Net) (TTM) + Intangible Assets Change (Net) (TTM))
More on SRRK
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Altman Z-score
- The full statement